{"meshTagsMajor":["Gene Amplification"],"meshTags":["Aged","Antibodies, Monoclonal","Antibodies, Monoclonal, Humanized","Antineoplastic Combined Chemotherapy Protocols","Bevacizumab","Carboplatin","Carcinoma, Non-Small-Cell Lung","Deoxycytidine","Epithelial-Mesenchymal Transition","Female","Gene Amplification","Humans","Protein Kinase Inhibitors","Proto-Oncogene Proteins c-met","Pyrazoles","Pyridines","Receptor Protein-Tyrosine Kinases","Receptors, Growth Factor","Treatment Outcome"],"meshMinor":["Aged","Antibodies, Monoclonal","Antibodies, Monoclonal, Humanized","Antineoplastic Combined Chemotherapy Protocols","Bevacizumab","Carboplatin","Carcinoma, Non-Small-Cell Lung","Deoxycytidine","Epithelial-Mesenchymal Transition","Female","Humans","Protein Kinase Inhibitors","Proto-Oncogene Proteins c-met","Pyrazoles","Pyridines","Receptor Protein-Tyrosine Kinases","Receptors, Growth Factor","Treatment Outcome"],"genes":["anaplastic lymphoma kinase","ALK","MET","ALK","ALK","MET","ALK"],"organisms":["9606","9606"],"publicationTypes":["Case Reports","Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.","title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.","pubmedId":"21623265"}